ReviewSynthetic and systems biotechnology2027
Toward engineered microbial chassis for growth-production balancing.
Review in Synthetic and systems biotechnology, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in erythritol production through synthetic biology and systems metabolic engineering.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The inherent conflict between cellular growth and product synthesis, arising from limited resource allocation and metabolic burden, fundamentally constrains the performance of microbial chassis. Traditional strategies that focus solely on flux intensification or knockout of competing pathways often face diminishing returns and may compromise cellular fitness, motivating the exploration of alternative engineering paradigms. Emerging approaches aim to modulate the growth-production trade-off across temporal, network-level, and spatial dimensions, thereby reframing this trade-off from a fixed physiological barrier into a tunable design parameter. This review systematically summarizes four complementary strategies: temporal decoupling via dynamic genetic circuits and phase-segregated cultivation; network-level metabolic resource optimization through redistribution of carbon flux, cofactors, and energy; spatial reorganization using enzyme colocalization, organelle compartmentalization, and modular microbial consortia; and digital and intelligent control frameworks that integrate real-time sensing, artificial intelligence (AI)-based prediction, and digital twin-enabled closed-loop optimization. The key insight is that decoupling does not eliminate competition but rather reschedules, redistributes, or relocalizes it, thereby achieving high production without sacrificing cellular robustness. Collectively, these multi-dimensional strategies transform the growth-production trade-off into a programmable engineering variable. Future efforts should focus on simplifying dynamic circuits, improving long-term genetic stability under industrial conditions, developing tools for non-model hosts, and engineering generally recognized as safe (GRAS) organisms with predictable trade-off management, paving the way for next-generation microbial cell factories that are both productive and resilient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.